Article
Molecularly targeted therapies for p53-mutant cancers.
Cellular and molecular life sciences : CMLS - 1 Nov 2017
Zhao Dekuang, Tahaney William M, Mazumdar Abhijit, Savage Michelle I, Brown Powel H
Abstract excerpt
The tumor suppressor p53 is lost or mutated in approximately half of human cancers. Mutant p53 not only loses its anti-tumor transcriptional activity, but also often acquires oncogenic functions to promote tumor proliferation, invasion, and drug resistance. Traditional strategies have been taken to directly target p53 mutants through identifying small molecular compounds to deplete mutant p53, or to restore its...
Topics
Join the communities discussing this publication.